Cost analysis of insulin degludec in comparison with insulin detemir in treatment of children and adolescents with type 1 diabetes in the UK
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Objective: With healthcare systems under increasing financial pressure from costs associated with diabetes care, it is important to assess which treatments provide clinical benefits and represent best value. This study evaluated the annual costs of insulin degludec (degludec) versus insulin detemir (IDet) in children and adolescents with type 1 diabetes (T1D) in the UK. Research design and methods: Using data from a randomized, treat-to-target, non-inferiority trial—BEGIN YOUNG 1—annual costs with degludec versus IDet in children and adolescents aged 1–17 years with T1D were estimated, as costs of these insulins and hyperglycemia with ketosis events. Analyses by age group (1–5, 6–11 and 12–17 years) and scenario (no ketosis benefit, no dose benefit, hyperglycemia with ketones >0.6 and >3.0 mmol/L and the additional costs of twice-daily IDet in 64% of patients) were also performed. Results: The mean annual cost per patient was estimated as £235.16 for degludec vs £382.91 for IDet, resulting in an annual saving of £147.75 per patient. These substantial cost savings were driven by relative reductions in the frequency of hyperglycemia with ketosis and basal insulin dose with degludec versus IDet. Annual savings in favor of degludec were observed across each age group (£122.63, £140.59 and £172.50 for 1–5, 6–11 and 12–17 years age groups, respectively). Five scenario analyses further demonstrated the robustness of the results, which included no ketosis or dose benefits in favor of degludec. Conclusions: Degludec provides appreciable annual cost savings compared with IDet in children and adolescents with T1D in a UK setting. While a cost-effectiveness analysis could incorporate the health impact of treatment complications better than the present cost analysis, the strong generalizability of the data from this study suggests that degludec can help healthcare providers to maximize health outcomes despite increasingly stringent budgets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Further improvements were confirmed when comparing second generation of ultra-long-acting basal to first-generation insulin analogs,1135,1137,1140–1145 which may translate into potential cost savings in real-world settings from avoiding severe hypoglycemic and hyperglycemic crises.1146”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1135]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several trials have demonstrated that physiologic regimens using basal insulin analogs may reduce hypoglycemia, and bolus insulin analogs may result in better control of PPG excursions for most persons with T1D.1132–1137”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1135]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International Diabetes Federation 2017
Carracher, A. M., Marathe, P. H., & Close, K. L. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12644 · Cited by 13,418
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 1×
“7 Accordingly, a key goal of insulin therapy is to maintain optimal blood glucose levels and prevent the development of these acute diabetes-related complications.(8) 9 New-generation long-acting insulin analogs with improved pharmacokinetic and pharmacodynamic profiles have been developed, and these have the potentia…”
BackgroundIntensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Hex, N., Bartlett, C., Wright, D., Taylor, M., & Varley, D. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03698.x · Cited by 819
Efficacy and safety of degludec versus glargine in type 2 diabetes.
Marso, S. P., McGuire, D. K., Zinman, B., Poulter, N. R., Emerson, S. S., Pieber, T. R., Pratley, R. E., Haahr, P.-M., Lange, M., Brown-Frandsen, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615692 · Cited by 574
Heise, T., Hermanski, L., Nosek, L., Feldman, A., Rasmussen, S., & Haahr, H. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01627.x · Cited by 397
Diabetic ketoacidosis and hyperglycemic hyperosmolar state
Wolfsdorf, J. I., Allgrove, J., Craig, M. E., Edge, J., Glaser, N., Jain, V., Lee, W. W., Mungai, L. N., Rosenbloom, A. L., Sperling, M. A., et al. (2014) · Pediatric Diabetes · doi:10.1111/pedi.12165 · Cited by 371 · cited 1×
“The risk of DKA in children and adolescents with established T1D is up to 10% per patientyear.(27) Depending on the severity of ketosis events and the experience of the pediatric carers, hyperglycemia with ketosis in children and adolescents with T1D may be managed at home and/or using healthcare facilities, leading t…”
BackgroundRatner, R. E., Gough, S. C. L., Mathieu, C., Del Prato, S., Bode, B., Mersebach, H., Endahl, L., & Zinman, B. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12032 · Cited by 346
Ultra‐long‐acting insulin degludec has a flat and stable glucose‐lowering effect in type 2 diabetes
Heise, T., Nosek, L., Bøttcher, S. G., Hastrup, H., & Haahr, H. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01638.x · Cited by 331
A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance
Haahr, H., & Heise, T. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0165-y · Cited by 226
Cited by
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Godman, B., Haque, M., Leong, T. D. D., Allocati, E., Kumar, S., Islam, S., Charan, J., Akter, F., Kurdi, A. B., Vassalo, C., et al. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.671961 · Cited by 45
(Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus
Hemmingsen, B., Metzendorf, M.-I., & Richter, B. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013498.pub2 · Cited by 37
Godman, B., Władysiuk, M., McTaggart, S., Kurdi, A. B., Allocati, E., Jakovljević, M., Kalemeera, F., Hoxha, I., Nachtnebel, A., Sauermann, R., et al. (2021) · BioMed Research International · doi:10.1155/2021/9996193 · Cited by 18
Advances in newer basal and bolus insulins: impact on type 1 diabetes
Vliebergh, J., Lefever, E., & Mathieu, C. (2020) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000599 · Cited by 18
Metadata
- Authors
- Thalange, N., Gundgaard, J., Parekh, W., & Tutkunkardas, D.
- Affiliations
- Al Jalila Foundation (AE)
- Novo Nordisk (Denmark) (DK)
- Novo Nordisk (United Kingdom) (GB)
- Corresponding author
- Thalange, Nandu
- Venue
- BMJ Open Diabetes Research & Care
- Publisher
- BMJ
- Published
- 2019-09
- Volume
- 7
- Issue
- 1
- Pages
- e000664
- ISSN
- 2052-4897 (ISSN-L)
- PMC
- PMC6731813
- OpenAlex
- W2971955106
- Cited by
- 7
- References
- 25
- Citations by year
- 2022: 1 · 2021: 5 · 2020: 1
- FWCI
- 1.42
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- BMJ Open Diabetes Research & Care (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Novo Nordisk A/S
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- insulin degludec, insulin detemir, type 1 diabetes, children and adolescents, cost analysis, basal insulin dose, cost reduction, insulin analogues, treatment cost comparison
- MeSH terms
- Insulin Detemir, Adolescent, Blood Glucose, Child, Child, Preschool, Cost-Benefit Analysis, Diabetes Mellitus, Type 1, Female, Follow-Up Studies, United Kingdom, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Infant, Male, Prognosis, Biomarkers, Insulin, Long-Acting
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cost analysis of insulin degludec in comparison with insulin detemir in treatment of children and adolescents with type 1 diabetes in the UK. https://app.cochat.ai/papers/10.1136/bmjdrc-2019-000664
- The paper
- Thalange, N., Gundgaard, J., Parekh, W., & Tutkunkardas, D. (2019). Cost analysis of insulin degludec in comparison with insulin detemir in treatment of children and adolescents with type 1 diabetes in the UK. BMJ Open Diabetes Research & Care. https://doi.org/10.1136/bmjdrc-2019-000664
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.